Influence of input rate on the stereospecific and nonstereospecific first pass metabolism and pharmacokinetics of metoprolol extended release formulations

The purpose of this study was to examine the influence of input rate on the stereoselective and nonstereoselective pharmacokinetics of metoprolol, α‐hydroxymetoprolol, and its acid metabolite. Extended release formulations (100 mg) of metoprolol with varying release rates (e.g., slow (S), moderate (...

Full description

Saved in:
Bibliographic Details
Published inChirality (New York, N.Y.) Vol. 14; no. 4; pp. 297 - 304
Main Authors Mistry, Bipin, Leslie, James L., Eddington, Natalie D.
Format Journal Article
LanguageEnglish
Published New York Wiley Subscription Services, Inc., A Wiley Company 2002
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The purpose of this study was to examine the influence of input rate on the stereoselective and nonstereoselective pharmacokinetics of metoprolol, α‐hydroxymetoprolol, and its acid metabolite. Extended release formulations (100 mg) of metoprolol with varying release rates (e.g., slow (S), moderate (M), and fast (F)) and an oral solution (OS, 50 mg) were administered to normal, healthy extensive metabolizers. Serial blood samples were collected over 48 h, plasma was obtained, and subsequently analyzed by a validated HPLC method with fluorescence detection. The mean Tmax of metoprolol after the S, M, F (4.43, 4.00, 3.14 h, respectively) was found to be different ( P < 0.05) as compared to the OS (2.07 h). The ratio of α‐hydroxymetoprolol/metoprolol was higher for the OS (1.26) vs. the S, M, and F (1.02, 0.96, 0.99). The S/R enantiomer ratios of the concentration for metoprolol, ACMB, and α‐hydroxmetoprolol were calculated at each time point and showed a significant difference ( P < 0.05) in the absorption phase (1–4 h) vs. terminal phase (8–16 h) for fast input (solution and fast extended release formulations). Based on these results, it would appear that input rate influences the pharmacokinetics of metoprolol, its metabolites, and their enantiomers. Chirality 14:297–304, 2002. © 2002 Wiley‐Liss, Inc.
Bibliography:istex:33617C67DE09103ECB1B3BA389A1A837F5E73D59
ark:/67375/WNG-LH7RBQVK-C
ArticleID:CHIR10045
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0899-0042
1520-636X
DOI:10.1002/chir.10045